Capital Trends: Chengtai New Materials, Weike Medical, Aintik Technology, Boyin Hearing, and Angiostone Biopharma Complete New Funding Rounds

Recently, TrendTec, announced the completion of an equity financing round exceeding 100 million yuan. This round was led by Vivo Capital, with participation from a fund under CICC Capital, and WinX Capital served as the exclusive financial advisor. The funds will be used for production line construction and subsequent product iteration and R&D. Formerly known as Suzhou TrendTec Medical Device Co., Ltd., founded in 2020, TrendTec primarily focuses on the research, production, and sales of ceramic materials for hip joints. TrendTec has completed the R&D and production of ceramic femoral heads and liners (the core components of hip joints).

Recently, Wuhan Vickor Medical Technology Co., Ltd. officially announced the successful completion of its Series C financing round, raising several hundred million RMB. The round was fully led by Bohua Capital, a well-known investment institution based in Liangxi District, Wuxi City. Vickor is an innovative medical device company specializing in minimally invasive interventions for structural heart disease and heart failure. Leveraging its core technological advantages in the cardiovascular field, Vickor has completed six rounds of equity financing since its establishment. Its product portfolio spans multiple cardiovascular treatment areas, including atrial shunt devices and various active devices for heart failure prevention and treatment, patent foramen ovale occluders for cardioembolic stroke prevention, transcatheter aortic valve replacement systems for valvular disease treatment, as well as related surgical accessories and consumables.

Recently, Eintik Technology (Shanghai) Co., Ltd. has completed a multi-million yuan Series A round of financing. This round of financing was led by top investment institution Fortune Venture Capital, and the funds will be used for core technology innovation, product development, market expansion, team expansion, and other purposes. Founded in 2013, Eintik Technology has established its R&D and production headquarters and metrology laboratory in Shanghai, an instrument R&D center in Guangzhou, and a sensor R&D center along with a 5,000-square-meter medical-grade production base in Changsha. The company also has branches in Beijing, Dongguan, Wuhan, Chengdu, and Xi'an. Eintik Technology specializes in full-focus ultrasonic phased array instruments, ultrasonic array probes, medical ultrasonic probes (such as ICE, IVUS, EUS, RDN), and customized intelligent ultrasonic systems. With a technological core in the development of high-end ultrasonic phased array (PAUT) products, it provides complete solutions such as ultrasonic probes, ultrasonic boards, and full ultrasonic testing systems, deeply empowering downstream ultrasound application customers.

Recently, Boyin Hearing Devices (Suzhou) Co., Ltd. announced the successful completion of a new round of strategic financing, raising nearly 100 million RMB. This round of financing was jointly led by Guangzhou Industrial Investment and Capital Glory, with Haoyue Capital serving as the exclusive financial advisor for this transaction. The success of this financing will not only provide solid financial support for Boyin Hearing in areas such as product development, market expansion, business innovation, and global deployment but also help Boyin Hearing seize the opportunities brought by the silver economy, gaining an early advantage during the critical growth phase of the hearing aid industry. This positions Boyin Hearing to potentially become a leading enterprise in China-produced hearing aids, achieving breakthroughs within the industry. Boyin Hearing was founded in Minhang District, Shanghai in 2019, received the "National High-tech Enterprise" title twice in 2021 and 2024, and was awarded the "Innovative Small and Medium-sized Enterprise" title in 2023.

Recently, Anges Biotech announced the completion of a $120 million Series C financing round, led by Bain Capital, with new investors Janus Henderson joining. Existing shareholders include OrbiMed, 3H Health Investment, Yonghua Capital, Yonhua Investment, Legend Capital, and Liche Investment. Founded in 2018, Anges Biotech focuses on the development of novel drugs for orthopedic conditions. Its lead pipeline candidate, AGA111, is currently advancing in Phase III clinical trials for spinal fusion in patients with degenerative disc disease. AGA2118 and AGA2115 are two sclerostin/DKK1 bispecific antibodies, currently in Phase II and Phase I clinical stages, respectively. The development of innovative orthopedic drugs has extremely high barriers, yet Anges Biotech's products have gained recognition from multiple investment institutions. In October 2023, the company completed a $46 million Series B+ financing round, followed by a second closing of a $40 million Series B+ round in February 2024. Now, it has successfully closed a $120 million Series C round, accumulating over $200 million across three financing rounds within a year.